Erschienen in:
01.09.2011 | Letter to the Editor
Combined chemotherapy with temozolomide and fotemustine in recurrent glioblastoma patients
verfasst von:
Paola Gaviani, A. Salmaggi, A. Silvani
Erschienen in:
Journal of Neuro-Oncology
|
Ausgabe 2/2011
Einloggen, um Zugang zu erhalten
Excerpt
Both temozolomide (TMZ) and fotemustine (FTM) are considered to be active agents in recurrent glioblastoma. The objective of this study is to assess the efficacy and toxicity profile of a sequential combination of TMZ and FTM in recurrent glioblastoma after standard treatment with TMZ and radiotherapy. The rationale for evaluating this regimen was, in part, the single-agent activity of both agents against recurrent glioblastoma. Furthermore, temozolomide seems to reduce O6-alkylguanine DNA alkyltransferase (AGAT) activity in vitro, suggesting that temozolomide might enhance the antitumor activity of fotemustine by reducing AGAT activity [
1]. …